Vernon G. Wong, MD, FACS, is the founder of Icon Bioscience and inventor of the Verisome drug delivery platform. Dr. Wong is a pioneer in the field of drug delivery dating back to the early 1970’s. He was the first clinical director of the National Eye Institute and was a tenured Professor at Georgetown University Medical School. Dr. Wong has published over 100 scientific papers. He co-founded and was the core patent holder in Oculex Pharmaceuticals, which was acquired by Allergan Pharmaceuticals for $245 million in 2002. In 2014, Dr. Wong was honored with the prestigious Visionary Award from the Foundation Fighting Blindness.
Prior to Icon Bioscience, Dr. Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals. In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals. Prior to Valera, Dr. Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation – a predecessor to Valeant Pharmaceuticals International. Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland.
David Tierney is the recipient of two Ernst & Young Entrepreneur of the Year® awards, first in 2005 and again in 2011. He was featured in the inaugural 2010 Irish Life Science 50 and in 2005, 2006, and 2011 was named one of the most inspiring people in the health sciences by PharmaVOICE 100.
Wendy Yee Murahashi, MD joined Icon Bioscience in October, 2011 and is responsible for all regulatory and clinical activities. Dr. Murahashi is a member of the American Academy of Ophthalmology. She is a board-certified ophthalmologist with subspecialty training in retina and vitreous. Dr. Murahashi previously served as Clinical Instructor at the Portland VA Hospital/Casey Eye Institute. Prior to joining Icon Bioscience, Dr. Murahashi was a Medical Director at Genentech/Roche with clinical trial responsibility involving the Lucentis® program.
Mr. Hector Casab joined Icon Bioscience in January 2014 and is responsible for all finance and accounting activities. Prior to joining the Company, Mr. Casab was head of Financial Planning at Onyx Pharmaceutical where he, was instrumental in supporting the company’s operational and financial growth of multiple product launches in oncology. He previously held roles in finance and operations at Genentech and Applied Biosystems. Mr. Casab earned his MBA from Santa Clara University.